This company crossed below the 50 day moving average, which is a sell sign to many people. Revenues and earnings doubled from last year. Thinks price is too high now. Recommends continuing to watch relative to 50 day moving average without moving below it. George will research Theragenics' main competitor Inis for next meeting.
Stock is very volatile.
Consensus of analysts recommend a hold or buy for the stock. Continue to watch - very possible buy for us. Earnings have been adversely affected by Asian crisis. 2 for 1 stock split in March 98. Majority of analysts recommend holding this stock.